In a report titled “Moderna Inc — INT melanoma + PDAC data confirmed at ESMO + adjuvant RCC + MIBC data coming in 2027…”, UBS analysts Michael Yee, Dina Elmonshed and Kyle Yang write that the Phase III adjuvant melanoma study’s late-breaker slot at ESMO is now confirmed, explaining the ~8-10% move in Moderna Inc (MRNA) shares. The team frames the readout as the near-term swing factor for the stock.
Continue Reading
This article is for pass holders.
30-Day Pass$12.00One-time purchase · no auto-renewalBuy 30 DaysSave $24.00
365-Day Pass$120.00
Already a pass holder? Sign in · Continue with Google